This review sought to define the emerging roles of urinary tumor DNA (utDNA) for diagnosis, monitoring, and treatment of bladder cancer. Building from early landmark studies the focus is on recent studies, highlighting how utDNA could aid personalized care.
Recent research underscores the potential for utDNA to be the premiere biomarker in bladder cancer due to the constant interface between urine and tumor. Many studies find utDNA to be more informative than other biomarkers in bladder cancer, especially in early stages of disease. Points of emphasis include superior sensitivity over traditional urine cytology, broad genomic and epigenetic insights, and the potential for non-invasive, real-time analysis of tumor biology. utDNA shows promise for improving all phases of bladder cancer care, paving the way for personalized treatment strategies. Building from current research, future comprehensive clinical trials will validate utDNA's clinical utility, potentially revolutionizing bladder cancer management.
Current oncology reports. 2024 Jun 05 [Epub ahead of print]
Joshua A Linscott, Hiroko Miyagi, Prithvi B Murthy, Sijie Yao, G Daniel Grass, Aram Vosoughi, Hongzhi Xu, Xuefeng Wang, Xiaoqing Yu, Alice Yu, Logan Zemp, Scott M Gilbert, Michael A Poch, Wade J Sexton, Philippe E Spiess, Roger Li
Department of Genitourinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA. ., Department of Genitourinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.